Skip to main content
Menu
US

AlphaLISA SureFire Ultra Human Phospho-NDRG1 (Ser330) Detection Kit, 100 assay points

The AlphaLISA™ SureFire® Ultra™ Human Phospho-NDRG1 (Ser330) assay is a sandwich immunoassay for quantitative detection of phospho-NDRG1 (Ser330) cellular lysates using Alpha Technology.

Feature Specification
Application Cell Signaling
Protocol Time 2h at RT
Sample Volume 30 µL

The AlphaLISA™ SureFire® Ultra™ Human Phospho-NDRG1 (Ser330) assay is a sandwich immunoassay for quantitative detection of phospho-NDRG1 (Ser330) cellular lysates using Alpha Technology.

Product Variants
Unit Size: 100 assay points
Part #:
ALSU-PNDRG1-A-HV
List Price
USD 708.00
Your online price:
Unit Size: 500 assay points
Part #:
ALSU-PNDRG1-A500
List Price
USD 2,393.00
Your online price:
Unit Size: 10,000 assay points
Part #:
ALSU-PNDRG1-A10K
List Price
USD 14,400.00
Your online price:
Unit Size: 50,000 assay points
Part #:
ALSU-PNDRG1-A50K
List Price
USD 46,000.00
Your online price:
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Total list price:
USD 0
Log in to view your online price

Overview

N-myc downstream-regulated gene 1 (NDRG1) is a stress response protein involved in cellular differentiation, apoptosis, and metastasis suppression. It functions as a tumor suppressor in some contexts, inhibiting epithelial-mesenchymal transition (EMT) and metastasis, while paradoxically supporting tumor progression in others through its regulation of iron metabolism. NDRG1 is upregulated in response to various cellular stresses, including hypoxia, DNA damage, and heavy metal exposure, aiding in cellular adaptation. It is widely expressed in various tissues and plays roles in cell growth, differentiation, lipid metabolism, and vesicular trafficking. NDRG1 expression is altered in cancers such as pancreatic, prostate, and colorectal cancer, where its role is context-dependent.

The AlphaLISA SureFire Ultra Human Phospho-NDRG1 (Ser330) Detection Kit is a sandwich immunoassay for the quantitative detection of phospho-NDRG1 (Ser330) in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • High-throughput screening for preclinical studies

Specifications

Application
Cell Signaling
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Protocol Time
2h at RT
Sample Volume
30 µL
Shipping Conditions
Shipped in Blue Ice
Target
NDRG1
Target Class
Phosphoproteins
Target Species
Human
Technology
Alpha
Therapeutic Area
Oncology
Unit Size
100 assay points

How it works

Phospho-AlphaLISA SureFire Ultra assay principle

The Phospho-AlphaLISA SureFire Ultra assay measures a protein target when phosphorylated at a specific residue.

The assay uses two antibodies which recognize the phospho epitope and a distal epitope on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of phosphoprotein present in the sample.

Assay Principle Phospho AlphaLISA SureFire Ultra

 

Phospho-AlphaLISA SureFire Ultra two-plate assay protocol

The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Phospho-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.

2 Plates Assay Protocol AlphaLISA Surefire Ultra Phospho Assay
Phospho-AlphaLISA SureFire Ultra one-plate assay protocol

Detection of Phosphorylated target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.

1 plate assay protocol AlphaLISA Surefire Ultra Phospho assay

Assay validation

Regulation of NDRG1 activity in endogenous cellular models

HeLa and A431 cells were seeded in a 96-well plate (40,000 and 60,000 cells/well respectively) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of Dp44mT, an iron chelator with antitumor activity, for 18 hours.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Phospho (Ser330 and Thr346) and Total NDRG1 levels were evaluated using respective AlphaLISA SureFire Ultra assays. Lysates were further diluted 1:5 in Lysis Buffer for analysis. For the detection step, 10 µL of cell lysate (approximately 800 HeLa cells and 1,200 A431 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, Dp44mT triggered a dose-dependent increase in the levels of Phospho (Ser330 and Thr346) and Total NDRG1 while Total Cofilin levels were unchanged (data not shown).

img-hela-cells-treated-with-dp44mt-alsu-pndrg1-a
Regulation of NDRG1 activity in endogenous cellular models

Loading...

Scroll Icon